Hikma Pharmaceuticals PLC HIK shares slipped 1.68% to £19.86 Monday, on what proved to be an all-around rough trading session ...

Hikma Pharmaceuticals PLC HIK shares shed 2.70% to £20.16 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.02% to ...

Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of KLOXXADO ® (naloxone HCl) Nasal Spray 8 mg, by Health Canada for the treatment of ...

In a report released today, James Gordon from J.P. Morgan maintained a Buy rating on Hikma Pharmaceuticals (HIK – Research Report), with a price target of p2,600.00. The company’s shares ...

Hikma Pharmaceuticals reported a strong financial performance for 2024, with revenue rising nine per cent to $3.13bn (£2.47bn ...

Healthcare & Pharmaceuticalscategory· December 23, 2024 US FDA approves Hikma's generic version of Novo's diabetes drug Victoza The U.S. Food and Drug Administration on Monday approved Hikma ...

The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from submission by Hikma of an Abbreviated New Drug Application to the U.S. Food and ...

Axsome Therapeutics has entered into a settlement agreement with Hikma resolving patent litigation related to Axsome’s product Sunosi (solriamfetol). The litigation, which is pending in the ...